Surgery Trasylol Law Suit News | Trasylol Lawyer

Until recently, Bayer’s anti-bleeding drug was used on a regular basis during heart surgery. Trasylol (Aprotinin) is widely used to decrease bleeding risk during coronary artery bypass graft (CABG) surgery. There are some common side effects that persist or become bothersome following use, including: constipation, diarrhea, difficulty urinating, infection (fever, chills, sore throat), lightheadedness, sleeplessness and/or vomiting. However, more severe Trasylol side effects may result. These include: severe allergic reactions (rash, hives, or swelling of mouth, face, lips or tongue), chest pain, decreased urination, fast or irregular heartbeat, severe stomach pain, sudden severe headache, numbness of an arm or leg, vision or speech changes or confusion.

If you have questions regarding whether this heart surgery drug was used please contact a Trasylol lawyer at Fields Law Firm and we can help you find out if it was used. There is no charge for us to help you investigate if the drug was administered during the procedure.

More specifically, a January 26, 2006, report in The New England Journal of Medicine indicates that Trasylol has been shown to cause adverse and even fatal side effects by significantly increasing the risk of a heart attack, stroke, kidney failure, and heart failure. This study, conducted by Dr. Dennis T. Mangano of the Ischemia Research and Education Foundation, sampled 4,374 heart surgery patients, and revealed that more patients receiving Trasylol experienced these side effects than patients receiving either no medications or other medications intended to decrease blood loss.

The study showed that Trasylol increased the risk of stroke by 181%, doubled the risk of kidney failure, increased the risk of encephalopathy (disease or disorder of the brain) and increased risk of heart attack by 50%. It supported the use of alternative options to avoid these side effects, such as aminocaproic acid and tranexamic acid.

FDA investigations followed and it was eventually revealed that Bayer failed to disclose an internal study that also uncovered these dangers. The study was conducted by i3, a global pharmaceutical services company, and demonstrated that use of Trasylol may increase the chance of death, serious kidney damage, congestive heart failure, and stroke compared to other drugs. Bayer acknowledged that it did not inform the FDA about the study, which examined 78,199 patients treated between April 2003 and March 2006, indicating that it was both a mistake to withhold it and that they had done so because it was preliminary in nature and raised significant questions on the study population, outcomes, and methodology.

This disclosure prompted the FDA to approve label changes in December 2006 that informed physicians and patients about the associated risks and to limit approved usage to specific situations. Ultimately, however, the FDA announced that the drug Trasylol was being removed from the marketplace.

We represent all Trasylol law suit clients on a contingency basis which means that there are never any legal fees unless we win compensation in your case. For a free no-obligation consultation please call toll free at 1-888-343-5375 or fill out our short online contact form and a Trasylol lawyer will contact you to answer any of your questions.

Trasylol Class Action Lawsuits

Trasylol lawsuits have been filed throughout the United States alleging that the heart surgery drug is a defective medication. They state that Trasylol (aprotinin) has caused kidney failure, heart attacks and strokes. These aprotinin lawsuits claim that Bayer, the drug’s manufacturer, marketed and sold Trasylol as a safe and effective medication to help prevent excessive bleeding during bypass surgery. They also claim that Bayer failed to adequately warn patients of its side effects. 

Bayer disputes the growing number of aprotinin studies that show increased risk of serious complications and death in Trasylol recipients. The causal link between Trasylol and these potentially fatal side effects has been known for several years and there is evidence that Bayer has known about the link between Trasylol and kidney failure as far back as the early 1980’s. The German scientist Dr. Juergen Fischer, director of the

Institute ofExperimental Medicine at theUniversity ofCologne, found severe incidents of kidney damage in animals that were given Trasylol more than 20 years ago. According to Dr. Fischer, he was surprised Bayer wasn’t interested in his findings.